logo-loader
HealthPharma & Biotech
Summit Therapeutics PLC

Summit Therapeutics shares DMD data

One poster at an industry conference this week will include validation data of muscle biopsy biomarkers used to assess utrophin modulator activity

1507118463_boydogcat.jpg
Duchenne Muscular Dystrophy is a muscle wasting disease that affects boys

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it and its collaboration partners will be presenting information related to its phase II clinical trial.

One poster at an industry conference this week will include validation data of muscle biopsy biomarkers used to assess utrophin modulator activity.

Utrophin control is central to Summit drug ezutromid, which is a potential treatment for boys with the incurable muscle wasting disease, Duchenne Muscular Dystrophy (DMD).

Flagship collaboration 

The biomarker breakthrough has come out of Summit’s collaboration with Flagship Biosciences.

"Developing new biomarkers capable of more reliably analysing muscle biopsies in clinical trials has been a major priority for Summit, and I am delighted with the progress made in our collaboration with Flagship,” said Dr David Roblin, the company’s chief medical officer.

“These automated techniques are capable of analysing thousands of muscle fibres in whole muscle biopsy sections, and we believe that their use could help us establish proof of mechanism for our utrophin modulator, ezutromid, in our ongoing PhaseOut DMD clinical trial."

The AIM and NASDAQ-listed life sciences company will also share baseline characteristics of patients enrolled into Summit's ongoing PhaseOut DMD study.

The conference, the 22nd International Congress of the World Muscle Society, is currently taking place in Saint-Malo, France.

Quick facts: Summit Therapeutics PLC

Price: £0.22

Market: AIM
Market Cap: £34.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) CEO Glyn Edwards caught up with Proactive Investors at the BIO CEO & Investor Conference in New York. Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol. Summit is...

on 02/11/2019

2 min read